Global TCR-Based Antibody Market Analysis By Target Antigen (NY-ESO-1, p53, WT-1, Ebv), By Indication (Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Other Indications), By End-Users (Hospitals, Specialized Clinics, Pharma & Biotech Research Laboratories, Gene Therapy Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Feb 2024
- Report ID: 84335
- Number of Pages: 227
- Format:
-
-
-
- Lion TCR
- GlaxoSmithKline
- Adaptimmune Therapeutics PLC
- Celgene Corporation
- Immunocore
- Kuur Therapeutics Limited
- Lion TCR Pte. Ltd.
- Kite Pharma
- Takara Bio Inc.
- Ziopharm Oncology Inc.
- Merck & Co. Inc.
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |